Biotech Values

[DewDiligence]

AMGN and NVS are at war over Aimovig, so they issue separate, essentially identical PRs re Aimovig data presented at AAN:

https://www.prnewswire.com/news-releases/amgen-to-highlight-extensive-long-term-safety-and-efficacy-data-of-aimovig-erenumab-aooe-across-the-spectrum-of-migraine-at-aan-annual-meeting-300843004.html

https://www.globenewswire.com/news-release/2019/05/02/1815773/0/en/Novartis-to-highlight-extensive-long-term-safety-and-efficacy-data-of-Aimovig-across-the-spectrum-of-migraine-at-AAN.html

Silly.